07/24/2026 | Press release | Distributed by Public on 07/24/2026 15:17
|
Delaware
|
84-1850815
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
3160 Porter Drive, Suite 250
|
||
|
Palo Alto, CA
|
94304
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
Large accelerated filer
|
☒
|
Accelerated filer
|
☐
|
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☐
|
|
Emerging growth company
|
☐
|
|
Exhibit
No.
|
Description
|
|
Form of Amended and Restated Certificate of Incorporation of the Registrant (1)
|
|
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (2)
|
|
|
Form of Amended and Restated Bylaws of the Registrant (3)
|
|
|
Specimen Common Stock Certificate (4)
|
|
|
5.1*
|
Opinion of Goodwin Procter LLP
|
|
23.1*
|
Consent of Independent Registered Public Accounting Firm to BridgeBio Pharma, Inc.
|
|
23.2*
|
Consent of Goodwin Procter LLP (included in Exhibit 5.1)
|
|
24.1*
|
Power of Attorney (included on signature page)
|
|
BridgeBio Pharma, Inc. Third Amended and Restated 2021 Stock Option and Incentive Plan and forms of award agreements thereunder (5)
|
|
|
107*
|
Filing Fee Table
|
|
(1)
|
Filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on July 3, 2019 and incorporated herein by reference.
|
|
(2)
|
Filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on June 23, 2025 and incorporated herein by reference.
|
|
(3)
|
Filed as Exhibit 3.2 to the Registrant's Registration Statement on Form S-4, filed on November 6, 2020 and incorporated herein by reference.
|
|
(4)
|
Filed as Exhibit 4.1 to the Registrant's Amendment No. 3 to Registration Statement on Form S-1, filed on June 24, 2019 and incorporated herein by reference.
|
|
(5)
|
Filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed on June 26, 2026 and incorporated herein by reference.
|
|
BRIDGEBIO PHARMA, INC.
|
|
|
By:
|
/s/ Neil Kumar
|
|
Neil Kumar, Ph.D.
|
|
|
Chief Executive Officer
|
|
| Signature | Title | Date | |
| /s/ Neil Kumar |
Chief Executive Officer and Director
|
July 24, 2026 | |
| Neil Kumar, Ph.D. |
(Principal Executive Officer)
|
||
| /s/ Thomas Trimarchi |
President and Chief Operating Officer
|
July 24, 2026 | |
| Thomas Trimarchi, Ph.D. |
(Principal Financial Officer)
|
||
| /s/ Maricel M. Apuli |
Chief Accounting Officer
|
July 24, 2026 | |
| Maricel M. Apuli |
(Principal Accounting Officer)
|
||
| /s/ Eric Aguiar |
Director
|
July 24, 2026 | |
| Eric Aguiar, M.D. | |||
| /s/ Jennifer E. Cook |
Director
|
July 24, 2026 | |
| Jennifer E. Cook | |||
| /s/ Douglas A. Dachille |
Director
|
July 24, 2026 | |
| Douglas A. Dachille | |||
| /s/ Ronald J. Daniels | Director | July 24, 2026 | |
| Ronald J. Daniels | |||
| /s/ Andrea J. Ellis |
Director
|
July 24, 2026 | |
| Andrea J. Ellis |
| /s/ Fred Hassan | Director | July 24, 2026 | |
| Fred Hassan | |||
| /s/ Charles Homcy | Director | July 24, 2026 | |
| Charles Homcy, M.D. | |||
| /s/ Andrew W. Lo | Director | July 24, 2026 | |
| Andrew W. Lo, Ph.D. | |||
| /s/ Frank P. McCormick | Director | July 24, 2026 | |
| Frank P. McCormick, Ph.D. | |||
| /s/ James C. Momtazee | Director | July 24, 2026 | |
| James C. Momtazee | |||
| /s/ Ali J. Satvat | Director | July 24, 2026 | |
| Ali J. Satvat | |||
| /s/ Hannah A. Valantine | Director | July 24, 2026 | |
| Hannah A. Valantine, M.D. |